

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## INTERVENTIONAL PROCEDURES PROGRAMME

### Equality impact assessment

#### IPG 364 Transperineal template biopsy and mapping of the prostate

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

#### Scoping

1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they?

There is a higher incidence of prostate cancer in the less socio-economically deprived areas, which may reflect higher uptake of prostate specific antigen (PSA) testing among affluent men (cancer registries of England and Wales)

Men with prostate cancer are covered by equalities legislation.

No potential issues were identified for ethnicity, disability, age, religion, sexual orientation or gender reassignment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified?

No preliminary view of the extent of these potential issues was given. No exclusions were applied.

3. Has any change to the scope (such as additional issues raised during

the Committee meeting) been agreed to highlight potential equality issues?

No

## Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No specific data relating to this procedure in difference socio-economic groups was identified in the literature included within the overview.

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?

No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligation to promote equality?

Not applicable

6. Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where?

No

**Approved by Programme Director (name):** Mirella Marlow

**Date:** 26 October 2010

### **Final interventional procedures document**

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could

make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

4. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?

No

**Approved by Programme Director (name):** Mirella Marlow

**Date:** 26 October 2010